him glp 1 Hims to begin selling GLP-1 microdosing treatments This advanced GLP After Philly Mag reporter Victor

In a conversation with Pharmaceutical Executive, Jay Bregman, CEO and co-founder of Andel, discusses the potential impact of the FDA's increased scrutiny on non-FDA approved GLP-1 products, particularly on the competitive landscape for obesity and diabetes therapies

Patients should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior

Per FDA's June 2026 warning letters, "clinically proven" language applied to compounded GLP-1 medications specifically is one of the flagged violation patterns - because the clinical trials that established GLP-1 efficacy tested FDA-approved finished products, not compounded preparations

For active subscribers, you can cancel future months at any time